Hereditary diffuse gastric cancer: Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers

Journal of Medical Genetics

Volumn 52, Issue 6, 2015, Pages 361-374

  van der Post, Rachel S ^a   Vogelaar, Ingrid P ^a   Carneiro, Fátima ^b,c,d,e   Guilford, Parry ^f   Huntsman, David ^g   Hoogerbrugge, Nicoline ^a   Caldas, Carlos ^h   Chelcun Schreiber, Karen E ⁱ   Hardwick, Richard H ^j   Ausems, Margreet G E M ^k   Bardram, Linda ^l   Benusiglio, Patrick R ^m   Bisseling, Tanya M ^a   Blair, Vanessa ⁿ   Bleiker, Eveline ^o   Boussioutas, Alex ^p,q   Cats, Annemieke ^r   Coit, Daniel ^s   DeGregorio, Lynn ^t   Figueiredo, Joana ^b,c   Ford, James M ^u   Heijkoop, Esther ^r   Hermens, Rosella ^a   Humar, Bostjan ^v   Kaurah, Pardeep ^w   Keller, Gisella ^x   Lai, Jennifer ⁱ   Ligtenberg, Marjolijn J L ^a   O'Donovan, Maria ^y   Oliveira, Carla ^b,c,d   Pinheiro, Hugo ^b,c   Ragunath, Krish ^z   Rasenberg, Esther ^aa   Richardson, Susan ^y   Roviello, Franco ^ab   Schackert, Hans ^ac   Seruca, Raquel ^b,c,d   Taylor, Amy ^y   Huurne, Anouk Ter ^ad   Tischkowitz, Marc ^h   Joe, Sheena Tjon A ^u   Van Dijck, Benjamin ^ad   Van Grieken, Nicole C T ^ae   Van Hillegersberg, Richard ^k   Van Sandick, Johanna W ^r   Vehof, Rianne ^a   Han Van Krieken, J ^a   Fitzgerald, Rebecca C ^h,y,af   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d University of Porto   (Portugal)

^e Centro Hospitalar Universitário de São João   (Portugal)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ No Stomach for Cancer Inc   (United States)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ Vinery Lane Surgery ^*  (New Zealand)

^o NETHERLANDS CANCER INSTITUTE   (Netherlands)

^p PETER MACCALLUM CANCER CENTRE   (Australia)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t The DeGregorio Family Foundation for Stomach and Esophageal Cancer Research   (United States)

^u STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v UNIVERSITY OF ZURICH   (Switzerland)

^w UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^x TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^y CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^z QUEEN S MEDICAL CENTRE   (United Kingdom)

^aa Patient Representative   (Netherlands)

^ab UNIVERSITY OF SIENA   (Italy)

^ac DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^ad Stichting CDH1   (Netherlands)

^ae VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^af MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN;

ADVANCED CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL PROTOCOL; COLORECTAL CANCER; DATA BASE; FAMILIAL CANCER; GASTRECTOMY; GASTRIC ENDOSCOPY; GASTROSCOPY; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY DIFFUSE GASTRIC CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MOLECULAR PATHOLOGY; MULTIMODALITY CANCER THERAPY; NUTRITION; PATIENT ADVOCACY; PATIENT CARE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; STOMACH CANCER; TUMOR BIOPSY; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; HEALTH SURVEY; HETEROZYGOTE; PROCEDURES; STOMACH NEOPLASMS;

BREAST NEOPLASMS; CADHERINS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GENETIC COUNSELING; GENETIC TESTING; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; STOMACH NEOPLASMS;

EID: 84930650698     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2015-103094     Document Type: Review

References (112)

1. Ferlay J. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11.
2. Oliveira C, Ferreira P, Nabais S, Campos L, Ferreira A, Cirnes L, Alves CC, Veiga I, Fragoso M, Regateiro F, Dias LM, Moreira H, Suriano G, Machado JC, Lopes C, Castedo S, Carneiro F, Seruca R. E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 2004;40:1897-903.
3. Keller G, Vogelsang H, Becker I, Plaschke S, Ott K, Suriano G, Mateus AR, Seruca R, Biedermann K, Huntsman D, Doring C, Holinski-Feder E, Neutzling A, Siewert JR, Hofler H. Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 2004;41:e89.
4. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber JE, Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011;13:651-7.
5. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 2000;6:2994-8.
6. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487-92.
7. Sereno M, Aguayo C, Guillen Ponce C, Gomez-Raposo C, Zambrana F, Gomez-Lopez M, Casado E. Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clin Transl Oncol 2011;13:599-610.
8. van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011;60:141-7.
9. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
10. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006;4:408-15.
11. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002;87:888-91.
12. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005;7:60.
13. Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011;10:1-9.
14. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs-its rational treatment. Ann Surg 1993;217:101-8.
15. Park SY, Ryu JK, Park JH, Yoon H, Kim JY, Yoon YB, Park JG, Lee SH, Kang SB, Park JW, Oh JH. Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver 2011;5:46-51.
16. Lynch HT, Snyder C, Davies JM, Lanspa S, Lynch J, Gatalica Z, Graeve V, Foster J. FAP, gastric cancer, and genetic counseling featuring children and young adults: a family study and review. Fam Cancer 2010;9:581-8.
17. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998;5:751-6.
18. Pollock J, Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol 2011;34:332-6.
19. Stanich PP, Francis DL, Sweetser S. The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 2011;9:e2-3.
20. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
21. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999;36:873-80.
22. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C, International Gastric Cancer Linkage C. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010;47:436-44.
23. Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, Hansford S, Hogervorst FB, Bosma AJ, Hofland I, Winter M, Huntsman D, Jonkers J, Bahlo M, Bernards R. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013;229:621-9.
24. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Almeida Santos T, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveria C, Pharoah PDP, Huntsman DG. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015. doi:10.1001/jamaoncol.2014.168
25. Wickremeratne T, Lee CH, Kirk J, Charlton A, Thomas G, Gaskin KJ. Prophylactic gastrectomy in a 16-year-old. Eur J Gastroenterol Hepatol 2014;26:353-6.
26. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-53.
27. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-72.
28. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006;14:21-33.
29. Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Nogues C, Fourme E, Colas C, Coulet F, Warcoin M, Grandjouan S, Sezeur A, Laurent-Puig P, Moliere D, Tlemsani C, Di Maria M, Byrde V, Delaloge S, Blayau M, Caron O. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet 2013;50:486-9.
30. Kim S, Chung JW, Jeong TD, Park YS, Lee JH, Ahn JY, Kim do H, Choi KD, Lee W, Song HJ, Lee GH, Chun S, Jung HY, Min WK, Kim JH. Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Fam Cancer 2013;12:503-7.
31. Choi HJ, Ki CS, Suh SP, Kim JW. Presymptomatic identification of CDH1 germline mutation in a healthy korean individual with family history of gastric cancer. Ann Lab Med 2014;34:386-9.
32. Yamada H, Shinmura K, Ito H, Kasami M, Sasaki N, Shima H, Ikeda M, Tao H, Goto M, Ozawa T, Tsuneyoshi T, Tanioka F, Sugimura H. Germline alterations in the CDH1 gene in familial gastric cancer in the Japanese population. Cancer Sci 2011;102:1782-8.
33. Yamada M, Fukagawa T, Nakajima T, Asada K, Sekine S, Yamashita S, Okochi-Takada E, Taniguchi H, Kushima R, Oda I, Saito Y, Ushijima T, Katai H. Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. Gastric Cancer 2014;17:750-6.
34. Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, Troy M, Pinder SE, Hanby A, Tomlinson I, Trembath RC, Roylance R, Simpson MA, Sawyer EJ. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014;110:1053-7.
35. Frebourg T, Oliveira C, Hochain P, Karam R, Manouvrier S, Graziadio C, Vekemans M, Hartmann A, Baert-Desurmont S, Alexandre C, Lejeune Dumoulin S, Marroni C, Martin C, Castedo S, Lovett M, Winston J, Machado JC, Attie T, Jabs EW, Cai J, Pellerin P, Triboulet JP, Scotte M, Le Pessot F, Hedouin A, Carneiro F, Blayau M, Seruca R. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J Med Genet 2006;43:138-42.
36. Kluijt I, Siemerink EJ, Ausems MG, van Os TA, de Jong D, Simoes-Correia J, van Krieken JH, Ligtenberg MJ, Figueiredo J, van Riel E, Sijmons RH, Plukker JT, van Hillegersberg R, Dekker E, Oliveira C, Cats A, Hoogerbrugge N, Dutch Working Group on Hereditary Gastric C. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer 2012;131:367-76.
37. Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009;18:1545-55.
38. Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010;13:1-10.
39. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008;216:295-306.
40. Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira-Carrico R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmao L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009;136:2137-48.
41. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009;69:2050-6.
42. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000;26:16-17.
43. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004;53:775-8.
44. Suriano G, Oliveira C, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C, Seruca R. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003;12:575-82.
45. Suriano G, Seixas S, Rocha J, Seruca R. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 2006;84: 1023-31.
46. Figueiredo J, Soderberg O, Simoes-Correia J, Grannas K, Suriano G, Seruca R. The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet 2013;21:301-9.
47. Simoes-Correia J, Figueiredo J, Lopes R, Stricher F, Oliveira C, Serrano L, Seruca R. E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. PLoS ONE 2012;7:e33783.
48. Sanches JM, Figueiredo J, Fonseca M, Duraes C, Melo S, Esmenio S, Seruca R. Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants. Eur J Hum Genet 2014. doi:10.1038/ejhg.2014.240
49. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012;91:97-108.
50. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE, Cargill M, Ford JM. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;32:2001-9.
51. Eijzenga W, Hahn DE, Aaronson NK, Kluijt I, Bleiker EM. Specific psychosocial issues of individuals undergoing genetic counseling for cancer-a literature review. J Genet Couns 2014;23:133-46.
52. Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG. Pregnancy after prophylactic total gastrectomy. Fam Cancer 2010;9:331-4.
53. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 2010;9:479-87.
54. Quinn GP, Pal T, Murphy D, Vadaparampil ST, Kumar A. High-risk consumers' perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genet Med 2012;14:191-200.
55. Simpson JL. Preimplantation genetic diagnosis at 20 years. Prenat Diagn 2010;30:682-95.
56. Gaston D, Hansford S, Oliveira C, Nightingale M, Pinheiro H, Macgillivray C, Kaurah P, Rideout AL, Steele P, Soares G, Huang WY, Whitehouse S, Blowers S, LeBlanc MA, Jiang H, Greer W, Samuels ME, Orr A, Fernandez CV, Majewski J, Ludman M, Dyack S, Penney LS, McMaster CR, Huntsman D, Bedard K. Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet 2014;10:e1004669.
57. Lim YC, di Pietro M, O'Donovan M, Richardson S, Debiram I, Dwerryhouse S, Hardwick RH, Tischkowitz M, Caldas C, Ragunath K, Fitzgerald RC. Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc 2014;80:78-87.
58. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006;4:262-75.
59. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004;53:814-20.
60. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001;92:181-7.
61. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344:1904-9.
62. Lewis FR, Mellinger JD, Hayashi A, Lorelli D, Monaghan KG, Carneiro F, Huntsman DG, Jackson CE, Caldas C. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001;130:612-17; discussion 7-9.
63. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Simoes M. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203:681-7.
64. Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Kingham K, Chun N, Ford JM, Longacre TA. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008;32:799-809.
65. Fujita H, Lennerz JK, Chung DC, Patel D, Deshpande V, Yoon SS, Lauwers GY. Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol 2012;36:1709-17.
66. Shaw D, Blair V, Framp A, Harawira P, McLeod M, Guilford P, Parry S, Charlton A, Martin I. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 2005;54:461-8.
67. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-10.
68. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004;41:508-17.
69. Hamilton LE, Jones K, Church N, Medlicott S. Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature. BMC Gastroenterol 2013;13:114.
70. Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE, Seruca R, Caldas C. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002;19:510-17.
71. Molleran V, Mahoney MC. Breast MRI. Philadelphia, PA, USA: Elsevier/Saunders, 2014.
72. Dunbar K, Canto M. Confocal endomicroscopy. Curr Opin Gastroenterol 2008;24:631-7.
73. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873-9.
74. Koea JB, Karpeh MS, Brennan MF. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol 2000;7:346-51.
75. Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, Hauptmann M, van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol 2013;39:686-93.
76. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care 2005;28:481-4.
77. Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 2007;11:142-7.
78. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219-25.
79. Choi J, Kim SG, Im JP, Kang SJ, Lee HJ, Yang HK, Kim JS, Kim WH, Jung HC, Song IS. Lymph node metastasis in multiple synchronous early gastric cancer. Gastrointest Endosc 2011;74:276-84.
80. Kang HJ, Kim DH, Jeon TY, Lee SH, Shin N, Chae SH, Kim GH, Song GA, Kim DH, Srivastava A, Park do Y, Lauwers GY. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010;72:508-15.
81. Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, Morgagni P, Saragoni L, de Manzoni G, Tomezzoli A. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006;94:275-80; discussion 4.
82. Wang G, Ceng G, Zhou B, Chen Y, Jin C, Feng X. Meta-analysis of two types of digestive tract reconstruction modes after total gastrectomy. Hepatogastroenterology 2013;60:1817-21.
83. Hackenson D, Edelman DA, McGuire T, Weaver DW, Webber JD. Prophylactic laparoscopic gastrectomy for hereditary diffuse gastric cancer: a case series in a single family. JSLS 2010;14:348-52.
84. Carneiro F, Charlton A, Huntsman D. Hereditary diffuse gastric cancer. In: Bosman FT, ed. WHO classification of tumours of the digestive system. 4th edn. IARC Sci Publ, 2010:59-63.
85. Dhingra S, Wang H. Nonneoplastic signet-ring cell change in gastrointestinal and biliary tracts: a pitfall for overdiagnosis. Ann Diagn Pathol 2011;15: 490-6.
86. Thompson IW, Day DW, Wright NA. Subnuclear vacuolated mucous cells: a novel abnormality of simple mucin-secreting cells of non-specialized gastric mucosa and Brunner's glands. Histopathology 1987;11:1067-81.
87. Rubio CA. Five types of pyloric cells in the antral mucosa of the stomach. Pathol Res Pract 1992;188:157-61.
88. Wang K, Weinrach D, Lal A, Musunuri S, Ramirez J, Ozer O, Keh P, Rao MS. Signet-ring cell change versus signet-ring cell carcinoma: a comparative analysis. Am J Surg Pathol 2003;27:1429-33.
89. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th edn. IARC Sci Publ, 2010.
90. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
91. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 2011;149:347-55.
92. Bardram L, Hansen TV, Gerdes AM, Timshel S, Friis-Hansen L, Federspiel B. Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study. Fam Cancer 2014;13:231-42.
93. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008;61:25-30.
94. Mills SE. Histology for pathologists. 3rd edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2007.
95. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999;155:337-42.
96. Lee AF, Rees H, Owen DA, Huntsman DG. Periodic acid-schiff is superior to hematoxylin and eosin for screening prophylactic gastrectomies from CDH1 mutation carriers. Am J Surg Pathol 2010;34:1007-13.
97. Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007;67:2480-9.
98. Mahmud N, Ford JM, Longacre TA, Parent R, Norton JA. Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation. J Clin Oncol 2015;33:e19-21.
99. Koyama T, Sekine S, Taniguchi H, Tsuda H, Ikegami M, Hano H, Kushima R. Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas. Hum Pathol 2011;42:1777-84.
100. van der Post RS, Bult P, Vogelaar IP, Ligtenberg MJ, Hoogerbrugge N, van Krieken JH. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch 2014;464:673-9.
101. Worster E, Liu X, Richardson S, Hardwick RH, Dwerryhouse S, Caldas C, Fitzgerald RC. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg 2014;260:87-93.
102. Friess H, Bohm J, Muller MW, Glasbrenner B, Riepl RL, Malfertheiner P, Buchler MW. Maldigestion after total gastrectomy is associated with pancreatic insufficiency. Am J Gastroenterol 1996;91:341-7.
103. Sakuta H, Suzuki T, Yasuda H, Wakiyama H, Hase K. Plasma vitamin B12, folate and homocysteine levels in gastrectomized men. Clin Nutr 2005;24:244-9.
104. Ruz M, Carrasco F, Rojas P, Codoceo J, Inostroza J, Basfi-Fer K, Valencia A, Csendes A, Papapietro K, Pizarro F, Olivares M, Westcott JL, Hambidge KM, Krebs NF. Heme-and nonheme-iron absorption and iron status 12 mo after sleeve gastrectomy and Roux-en-Y gastric bypass in morbidly obese women. Am J Clin Nutr 2012;96:810-17.
105. Adachi S, Kawamoto T, Otsuka M, Todoroki T, Fukao K. Enteral vitamin B12 supplements reverse postgastrectomy B12 deficiency. Ann Surg 2000;232:199-201.
106. Tondapu P, Provost D, Adams-Huet B, Sims T, Chang C, Sakhaee K. Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg 2009;19:1256-61.
107. Mine S, Sano T, Tsutsumi K, Murakami Y, Ehara K, Saka M, Hara K, Fukagawa T, Udagawa H, Katai H. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010;211:628-36.
108. Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, Jun KH, Song KY, Jeon HM, Chin HM, Park CH, Chung IS. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil 2011;23:e191-6.
109. Miholic J, Meyer HJ, Muller MJ, Weimann A, Pichlmayr R. Nutritional consequences of total gastrectomy-the relationship between mode of reconstruction, postprandial symptoms, and body-composition. Surgery 1990;108:488-94.
110. No Stomach For Cancer. http://www.nostomachforcancer.org/
111. DeGregorio Family Foundation for Stomach and Esophageal Cancer Research. http://www.degregorio.org/
112. Stichting CDH1. http://stichting-cdh1.nl/